Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine

Ignacio Olivera, Carlos Grau, Hugo Dibarboure, Juan Pablo Torres, Gustavo Mieres, Luis Lazarov, Fabián P. Alvarez and Juan Guillermo López Yescas*

Abstract

Background: The phased withdrawal of oral polio vaccine (OPV) and the introduction of inactivated poliovirus vaccine (IPV) is central to the polio ‘end-game’ strategy.

Methods: We analyzed the cost implications in Chile of a switch from the vaccination scheme consisting of a pentavalent vaccine with whole-cell pertussis component (wP) plus IPV/OPV vaccines to a scheme with a hexavalent vaccine with acellular pertussis component (aP) and IPV (Hexaxim®) from a societal perspective. Cost data were collected from a variety of sources including national estimates and previous vaccine studies. All costs were expressed in 2017 prices (US$ 1.00 = $Ch 666.26).

Results: The overall costs associated with the vaccination scheme (4 doses of pentavalent vaccine plus 1 dose IPV and 3 doses OPV) from a societal perspective was estimated to be US$ 12.70 million, of which US$ 8.84 million were associated with the management of adverse events related to wP. In comparison, the cost associated with the 4-dose scheme with a hexavalent vaccine (based upon the PAHO reference price) was US$ 19.76 million. The cost of switching to the hexavalent vaccine would be an additional US$ 6.45 million. Overall, depending on the scenario, the costs of switching to the hexavalent scheme would range from an additional US$ 2.62 million to US$ 6.45 million compared with the current vaccination scheme.

Conclusions: The switch to the hexavalent vaccine schedule in Chile would lead to additional acquisition costs, which would be partially offset by improved logistics, and a reduction in adverse events associated with the current vaccines.

Keywords: Vaccination, Cost, Pediatric, Polio
aged <5 years, representing $231 billion in the value of statistical lives saved [3].

Poliomyelitis is an acute paralytic disease caused by three poliovirus serotypes [4, 5]. The use of the formalin-inactivated Salk polio vaccine (IPV) (first introduced in 1955) and the Sabin oral polio vaccine (OPV) (introduced in the early 1960’s) in routine immunization programs and supplemental mass vaccination campaigns has led to the elimination or near elimination of poliomyelitis and polioviruses circulation from many countries [6]. Nonetheless, it is estimated that there are 10–20 million individuals worldwide living with poliomyelitis-related disabilities [7], though very little is known about the socio-economic consequences and healthcare costs of the disabilities.

OPV has been the vaccine of choice for the Global Polio Eradication Initiative (GPEI) of the World Health Organization (WHO) because of its low cost, ease of administration and superiority in inducing mucosal immunity [8, 9]. However, OPV vaccination carries some risks, namely the appearance of vaccine-associated paralytic poliomyelitis cases (VAPP) and the emergence of vaccine derived polioviruses (VDPV) [10]. The strategy for the elimination of all polioviruses, referred to as the polio endgame, includes two steps synchronized around the world for all countries still vaccinating with OPV. First the switch from trivalent OPV to bivalent OPV (as wild type OPV-2 no longer circulates), and second the switch from OPV to IPV in routine childhood immunization programs in order to avoid OPV-derived cases [10–12].

Vaccination against polio in Chile began in 1961 [13], and by 1975 the last case of wild polio was detected, 19 years before the South America region was declared polio-free [14]. As part of the Polio Eradication and Endgame Strategic Plan developed by the GPEI, the World Health Organization Strategic Advisory Group of Experts (WHO-SAGE) has recommended as a first step that all countries introduce at least one dose of IPV into their routine immunization programs [15], before the complete switch to immunization with IPV [16].

Combination vaccines have been developed and introduced in routine childhood immunization programs, allowing individuals to be simultaneously vaccinated against multiple infectious diseases including diphtheria, tetanus, pertussis, poliomyelitis, Hib and hepatitis B (HepB) [17, 18]. Combination vaccines have the additional advantages of increased vaccination coverage rates [19], improved vaccination timeliness, and reduction of the number injections required in an increasingly crowded immunization schedule [20–22].

Chile introduced a combined bivalent vaccine for diphtheria and pertussis (DP) into the routine childhood immunization program in 1950, which was later replaced by the trivalent vaccine that included pertussis (DTwP) in 1975. The tetravalent vaccine including Hib (DTwP-Hib) was introduced in 1996 and the switch to the pentavalent vaccine including HepB (DTwP-Hib-HepB) occurred in 2006. In 2015, Chile started to replace the 2-month OPV dose (used in combination with the pentavalent vaccine) with IPV in line with WHO-SAGE recommendations to support the polio eradication endgame strategy, with the vaccination series completed with OPV (used in combination with the pentavalent vaccine) administered at 4, 6 and 18 months. Then in February 2018, the hexavalent vaccine including IPV (DTaP-IPV-HepB-Hib) was introduced at 2 and 4 month and the vaccination series completed with the pentavalent (DTwP-Hib-HepB) vaccine and OPV both administered at 6 and 18 months [23]. More recently, in December 2018, the hexavalent (DTaP-IPV-HepB-Hib) vaccine was recommended to provide all four polio vaccine doses at 2, 4, 6 and 18 months [24].

In Latin America, there is an increasing role for economic evaluations in supporting evidence-based decision making. This has also applied to the assessment of new vaccines or immunization programs (see for example Glassman et al. 2016 [25], and the Pan-American Health Organization (PAHO) [26]). Most of these studies are based on cost-effectiveness and/or cost-utility analysis.

We undertook this study to assess the economic impact of moving from the Chilean vaccination scheme in 2016 to a new program based upon the use of a full hexavalent (DTaP-IPV-HepB-Hib) vaccine scheme at 2, 4, 6 and 18 month of age. Because the new scheme represents a replacement of antigens, for both OPV to IPV and wP to aP, without any significant difference in the efficacy of the switched antigens, we considered a cost-minimization analysis as the most appropriate economic evaluation methodology to utilize.

Methods
The objective of the current study was to describe and analyze the cost differences between switching from the current vaccination scheme to a new scheme, based on a fully-liquid ready-to-use hexavalent vaccine. We considered a full switch between schemes to the new hexavalent program comprising 4 doses (three primary and one ‘booster’ doses). The programs were analyzed from the societal perspective.

The study cohort (infants eligible for vaccination) was taken from national statistics produced by the Chilean government [27]. The vaccination scheme in 2016, which consists of 4 doses of wP-containing pentavalent vaccine (DTwP-Hib-HepB) plus 1 dose IPV and 3 doses OPV, was based on the program from the Ministry of Health [23, 28] and the new scheme was assumed to replicate the same vaccine antigen coverage including
the use of a 'booster' dose at 18 months. Vaccination coverage rates were taken as the average of those achieved in Chile between 2006 and 2015 [29].

Adverse event rates, associated with vaccination, were taken from previously published studies [30, 31] and included: seizures (with or without fever) and hypotonia-hyporesponsiveness syndrome after wP vaccines, edema, vomiting, anorexia, pain and redness or irritation of the skin. Full details of the values used can be found in Table 1. For seizures and other neurological effects such as hypotonic-hyporesponsiveness, data were taken from two studies which estimated seizures (with or without fever) and hypotonia syndrome; hypotonic-hyporesponsiveness episodes after wP vaccines was estimated at 1 case/1750 vaccinated i.e. 0.57 cases/1000 doses [32] and 0.12 cases/1000 doses with the aP vaccines [31].

It was assumed that some of the more serious adverse events result in costs being incurred, for example through medical consultations, absenteeism and medication. Those events which were deemed to result in medical treatment were severe injection site edema > 20 mm; severe pain; severe irritation due to agitation or persistent acute crying; and drowsiness. Based upon expert opinion, we assumed that 20% would be the appropriate consultation rate. For those suffering from some more serious neurological manifestations (e.g. convulsions with or without fever, hypotonia-hyporesponse syndrome) it was assumed that all cases consulted were hospitalized for 1.5 days, and had a single post-discharge outpatient consultation.

Cost data was taken from a variety of sources including PAHO, previous vaccine studies and national estimates and included: antipyretics use, patient transfers/travel expenses, medical consultation, hospitalization, lost work time/days for parental care, time to administer the vaccine dose [33], cost of vaccine distribution, cost of the cold chain, costs for programmatic errors, costs of OPV, IPV, hexavalent and pentavalent vaccines, cost for the purchase of the hexavalent vaccine in the private sector. Details of the costs included can be found in Table 2.

All costs are in 2017 prices. Prices were converted from Chilean pesos into US$ using an exchange rate of $Ch 666.26 = US$1 (April 2017) [38].

Four scenarios were modelled (Table 3); all were conducted from a social perspective. In Scenario 1, the cost of the scheme with hexavalent vaccine was estimated according to its reference price in the Revolving Fund of PAHO for 2017 and compared with the cost of the 2016 plan, which implies the expenditure of pentavalent vaccine (reference price of the bidding in place), plus spending on polio vaccine according to its average price in the Revolving Fund and the additional costs involved in the simultaneous scheme with the pentavalent vaccine. In this scenario, the price of the polio vaccine was the average of the prices of 1 dose of IPV and 3 doses of OPV.

Scenario 2 compared the current pentavalent vaccination plan and an additional 4-dose full IPV scheme versus vaccinating with hexavalent vaccine. The cost of the program with hexavalent vaccine was estimated based on its reference price in the Revolving Fund of PAHO of

| Table 1 Adverse event rates for vaccines containing whole-cell pertussis and acellular pertussis components [30] |
|-------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Adverse Event           | 1st Dose                 |                           | 2nd Dose                 |                           | 3rd Dose                 |                           |
|                         | Whole-cell vaccine (%)   | Acellular vaccine (%)     | Whole-cell vaccine (%)   | Acellular vaccine (%)     | Whole-cell vaccine (%)   | Acellular vaccine (%)     |
| Fever between 100.1°-101 °F (37.8–38.3°C) | 24.3                     | 2.3                       | 28.8                     | 12.8                     | 27.8                     | 15.2                      |
| Fever between 101.1°-102 °F (38.39–38.89 °C) | 3.0                      | 0.8                       | 3.9                      | 0.8                      | 7.3                      | 2.3                       |
| Fever > 102 °F (> 38.9°C) | 0                        | 0                         | 1.4                      | 0.8                      | 2.6                      | 0                         |
| Skin reddening (1-20 mm) | 40.8                     | 13.5                      | 41.6                     | 24.1                     | 44.4                     | 25.8                      |
| Skin reddening (> 20 mm) | 8.6                      | 0.8                       | 6.1                      | 1.5                      | 3.2                      | 3.0                       |
| Edema (1-20 mm)          | 23.2                     | 7.5                       | 26.6                     | 16.5                     | 30.1                     | 14.4                      |
| Edema (> 20 mm)          | 16.5                     | 0.8                       | 9.5                      | 0.8                      | 5.6                      | 3.8                       |
| Moderate pain            | 17.6                     | 2.3                       | 12.6                     | 3.0                      | 12.0                     | 3.8                       |
| Severe pain              | 9.7                      | 0                         | 6.1                      | 0                        | 3.8                      | 0                         |
| Moderate irritation       | 16.8                     | 3.8                       | 16.5                     | 6.0                      | 12.6                     | 4.5                       |
| Severe irritation         | 3.8                      | 0.8                       | 7.0                      | 0.8                      | 4.7                      | 0.8                       |
| Use of anti-pyretics     | 60.5                     | 35.3                      | 59.8                     | 35.3                     | 61.4                     | 33.3                      |
| Fatigue                  | 43.5                     | 28.6                      | 31.0                     | 14.3                     | 24.6                     | 14.4                      |
| Reduced appetite         | 19.5                     | 7.5                       | 16.5                     | 4.5                      | 14.3                     | 12.1                      |
| Vomiting                 | 7.0                      | 3.0                       | 4.5                      | 1.5                      | 5.3                      | 3.8                       |
### Table 2: Costs included

| Healthcare resource                                      | Value (US$) | Source                                                                 |
|----------------------------------------------------------|-------------|------------------------------------------------------------------------|
| Outpatient clinic                                        | 13.97       | Arancel MAI 2018 MINSAL, Chile [34]: https://www.fonasa.cl/sites/fonasa/prestadores/normativa/aranceles#modalidad-de-atencion-institucional%2D%2Dmai- |
| Pediatric hospitalization (day)                          | 556         | Arancel MAI 2018 MINSAL, Chile [35]: https://www.fonasa.cl/sites/fonasa/prestadores/normativa/aranceles#modalidad-de-atencion-institucional--mai- |
| Anti-pyretic (Paracetamol 100 mg/mL)                     | 6.89        | CENABAST, Chile [36]: https://www.cenabast.cl/compras-cenabast-vigentes |
| Travel to hospital (2 journeys per visit)                | 1.11        | Assumption: It was assumed that the transfer to ambulatory as well as to the emergency and hospitalization, required 2 transfers. The reference was transfer by bus, which costs 740 Chilean pesos, with an exchange rate to 666.26 pesos per US$, corresponds to a cost of US$ 1.11. |
| Loss of working time to attend outpatients/hospital       | 32.99 (per day. Assume 1 day per OP visit and 1.5 days per hospitalization) | Assumption: The average value of a working day corresponds to 21,977.26 Chilean pesos, equivalent to US$ 32.99. It was assumed that the loss would be 1 day in case of transfer to outpatient clinic and 1.5 days in the case of hospitalization. |
| Price of hexavalent (DTaP-IPV-HepB-Hib) vaccine           | 19.80       | PAHO [37]: https://www.paho.org/hq/index.php?option=com_docman&view=download&category_slug=vacunas-9980&alias=38125-fondo-rotatorio-precios-vacunas-2017-125&Itemid=270&lang=es |
| Price of IPV in pre-filled syringe                        | 5.3         | Sanofi Pasteur and PAHO [37]: https://www.paho.org/hq/index.php?option=com_docman&view=download&category_slug=vacunas-9980&alias=38125-fondo-rotatorio-precios-vacunas-2017-125&Itemid=270&lang=es |
| Price of IPV plus cost of syringe                         | 2.1         | Price of vial (US$ 1.9) + syringe, PAHO [37]: https://www.paho.org/hq/index.php?option=com_docman&view=download&category_slug=vacunas-9980&alias=38125-fondo-rotatorio-precios-vacunas-2017-125&Itemid=270&lang=es |
| Price of IPV where supply difficulties require two different presentations to be used | 3.6         | Average between pre-filled syringe and vial, PAHO [37]: https://www.paho.org/hq/index.php?option=com_docman&view=download&category_slug=vacunas-9980&alias=38125-fondo-rotatorio-precios-vacunas-2017-125&Itemid=270&lang=es |
| Price of the bivalent oral polio vaccine (10-dose bottle) | 0.32 (allowing for wastage) | PAHO [37]: https://www.paho.org/hq/index.php?option=com_docman&view=download&category_slug=vacunas-9980&alias=38125-fondo-rotatorio-precios-vacunas-2017-125&Itemid=270&lang=es |
| Price of the pentavalent (DTwp-Hib-HepB) vaccine (per dose) | 2.85        | Last adjudicated bidder for the pentavalent vaccine: GSK at US$ 1898 x dose. http://www.mercadopublico.cl/Procurement/Modules/RFB/DetailsAcquisition.aspx?qs=K4W9Y4g072527ulmJWg== |
| Administration of vaccine (12 mins)                      | 5.69 (Nursing assistant/hr) | Assumption: Includes: undressing the child, preparing the vaccine, applying, and registering in all documents and in the Nominal Registration System. It was assumed that the salary of a Nursing Assistant (who administers the vaccine at the vaccination center) would be 500,000 Chilean pesos, corresponding to 2727 Chilean pesos per day for 22 days per month from Monday to Friday. If the working day was 6 h, then the value of nurses time for the hour would be 3788 Chilean pesos, US$ 5.69 |
| Additional distribution costs of pentavalent (DTwp-Hib-HepB) plus polio vaccine | 0.15        | Assumption: A higher cost was assumed for distribution of vaccines in the pentavalent arm simultaneously with the polio vaccine. The cost of distribution per dose of vaccine was US$ 0.15. This cost was provided Sanofi Pasteur Chile from internal data. |
| Delivery costs of vaccine                                 | 3120 (per quarter) | Assumption: According to the size of the boxes, 9259 doses would be required to complete 1 cubic meter. Each maintenance panel was 1 cubic meter. The total doses would equal 104 panels, but an adequate stock per quarter was assumed with quarterly deliveries. The panel requirement was 26 per quarter (each month of the quarter) and with a cost of US$ 40 per panel per month, makes a total quarterly cost of US$ 3120. This cost was provided Sanofi Pasteur Chile from internal data. |
| Level of errors in non-hexavalent vaccine program associated with simultaneous vaccination | 1%          | Assumption: These errors could be due to the lack of inputs and the parents’ discomfort in front of the number of applications on the same day, with the refusal to accept it. This percentage was the result |
2017 and compared with the cost of the current plan modified with the inclusion of a 4-dose full IPV scheme, which includes expenditure on the pentavalent vaccine (reference price of the tender in place), plus the average price of IPV in the PAHO Revolving Fund for 2017 for a 4-dose full IPV scheme and the additional costs which assumes the simultaneous scheme with the pentavalent vaccine. In this scenario, the price of IPV was the average of the prices of two different vaccines presentations in the Revolving Fund since there is a real possibility that the distribution of this vaccine through the Revolving Fund may vary due to supply issues.

Scenario 3 was similar to Scenario 2 above, but used the lowest reported price for IPV (US$ 2.10) reported in the PAHO revolving fund. Scenario 4, was also based on Scenario 2 above, but used the highest reported price for IPV (US$ 5.10) reported in the PAHO revolving fund.

Results

The population of Chile was found to be relatively stable in the period 2010–2017 (Table 4). We used the data from the last full recorded year (2016) with a cohort of children aged < 1 year (249,552) and aged under 2 years (249,221) in this analysis.

From a societal perspective, the costs associated with the management of adverse events with the 2016 vaccination scheme (4 doses pentavalent vaccine + 1 dose IPV and 3 doses OPV) are US$ 8.84 million (Table 5) and those for the current vaccines used, US$ 3.86 million (Table 6). Thus, the overall costs associated with 2016 vaccination scheme are US$ 12.70 million. In comparison, the costs associated with the 4-dose scheme with a hexavalent vaccine (based upon the PAHO reference price) would be US$ 19.76 million (Table 6). Therefore, the cost of switching to the hexavalent vaccine would be

| Scenario 1 | Pentavalent (DTwP-Hib-HepB) vaccine | Hexavalent (DTaP-IPV-HepB-Hib) vaccine |
| Scenario 2 | Pentavalent (DTwP-Hib-HepB) vaccine | Hexavalent (DTaP-IPV-HepB-Hib) vaccine |
| Scenario 3 | Pentavalent (DTwP-Hib-HepB) vaccine | Hexavalent (DTaP-IPV-HepB-Hib) vaccine |
| Scenario 4 | Pentavalent (DTwP-Hib-HepB) vaccine | Hexavalent (DTaP-IPV-HepB-Hib) vaccine |

bOPV bivalent oral polio vaccine, IPV inactivated polio vaccine
an additional US$ 6.45 million (Scenario 1). The results for the other three scenarios are also shown in Table 6. The costs of switching to the hexavalent scheme would range from additional US$ 2.62 million to US$ 6.45 million compared with the current vaccination scheme according to the scenario considered.

The difference of 30,944 doses in the amount of hexavalent and the other vaccines is based on 7736 children in the private market receiving four doses of Hexavalent (3 + 1 scheme), and was assumed that the ministry of health would reimburse the vaccine for the whole cohort.

In Scenario 4, the switch to the hexavalent scheme would cost US$ 2.62 million.

**Discussion**

In this study, we estimated and compared the difference in costs generated by two schemes with similar health outcomes but differences in the costs and safety, which were largely associated with logistics and adverse events management. The four scenarios analyzed considered two different approaches towards polio immunization, moving from a representation of Chile’s 2016 approach (1 dose of inactivated polio vaccine, followed by 3 doses of OPV) towards the GPEI objective in which OPV should be suspended as soon as possible, which means that the complete IPV scheme (i.e. all doses used are IPV) would become the preferred option. Several countries in Latin America have already expressed interest in a complete IPV scheme, similar to that introduced in Uruguay in 2012, but the supply of IPV has not been adequate or sufficiently reliable to fully comply with that policy. Based upon the PAHO reference prices, use of the hexavalent vaccine implies a greater expense versus simultaneous vaccination using the current pentavalent plus polio vaccines. However, the existence of more adverse events in the current scheme associated with wP compared to the aP formulation of the hexavalent scheme minimizes the cost difference between the two schemes.

There have been relatively few published assessments of the economic impact of hexavalent vaccines. A study in France (where the hepatitis B vaccine coverage was low) of a hexavalent combination vaccine, found that the public price associated with a break-even point would be €53.77. The annual additional reimbursed cost of protecting an infant against the risk of hepatitis B was €28.20 per child, or about €21 million for an annual cohort of 760,000 births (total cost, €35 million) [39]. Whilst there are problems with direct comparisons between France and Chile, due to differences in the healthcare systems and relative GDP of the two countries, the use of a hexavalent vaccine in our hypothetical model does produce similar increase in overall costs when factoring in the lower population covered in Chile.

| Variable | First dose | Second dose | Third dose | Fourth dose | Total |
|----------|------------|-------------|------------|-------------|-------|
| HCP visits, hospitalizations and healthcare system costs | 788,005 | 740,377 | 674,001 | 664,723 | 2,868,006 |
| Pocket expenses, private vaccine payment | 548,645 | 548,645 | 548,645 | 548,645 | 2,194,580 |
| Transportations costs for adverse events | 460,080 | 40,182 | 21,006 | 20,749 | 128,016 |
| Absenteeism for parents for adverse events | 686,022 | 598,436 | 317,221 | 304,666 | 1,906,345 |
| Administration time for additional vaccine | 269,567 | 269,567 | 266,730 | 263,542 | 1,069,406 |
| Distribution costs of additional vaccine | 35,561 | 35,561 | 35,187 | 34,766 | 141,075 |
| Programmatic errors due to simultaneous vaccination\(^a\) | 129,767 | 129,767 | 129,767 | 129,595 | 518,896 |
| Cold chain costs for additional vaccine\(^b\) | 3120 | 3120 | 3120 | 3120 | 12,480 |
| Total | 2,507,667 | 2,365,655 | 1,995,667 | 1,969,806 | 8,838,805 |

\(^a\)For example, administration of all required vaccines at any scheduled visit may not be strictly according to the national schedule due to limits in stock availability or parental decision, which necessitates additional visits to receive all required vaccines (with their associated costs)

\(^b\)Based on assumption of the volume of both schemes; considering that the size of vaccination cohort would be same for the hexavalent, as well as the pentavalent plus polio vaccine programs, then there would be a space reduction of 50% (1 vaccine versus 2 vaccines). The calculation of the cost of the square meter (cold chain pallet) was based on the additional square meters required for pentavalent plus polio vaccine program according to the Chilean cohort

HCP Health Care Provider

Table 4 Population of Chile (projection of the 2 cohorts, 2007–2017)

| Age | Year | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
|-----|------|------|------|------|------|------|------|------|------|------|------|------|
| Total | 16,504,869 | 16,686,853 | 16,876,767 | 17,066,142 | 17,255,527 | 17,444,799 | 17,631,579 | 17,819,054 | 18,006,407 | 18,191,884 | 18,373,917 |
| 0 | 235,457 | 242,535 | 248,363 | 250,453 | 248,203 | 244,493 | 243,846 | 246,478 | 248,803 | 249,552 | 248,757 |
| 1 | 231,072 | 235,687 | 242,775 | 248,628 | 250,790 | 248,599 | 244,906 | 244,260 | 246,895 | 249,221 | 249,979 |

Table 5 Summary of the additional costs involved in the use of vaccines containing whole-cell pertussis component (societal perspective)
Our findings are supported by a previous study conducted in Latin America. An earlier study in Mexico examined the impact of moving from OPV to IPV vaccination schedule. The authors found that changing from the existing OPV-based routine schedule and intensive supplementary activities to a sequential IPV-OPV routine schedule using a pentavalent and IPV/OPV vaccines would save US$ 14.52 per vaccinated child, and changing to a full IPV routine schedule would save US$ 9.41 per vaccinated child [40]. This latter figure is consistent with the outcomes reported in Scenario 4 of our analysis using the lower price for the hexavalent vaccine.

A similar cost-minimization analysis has been performed for hexavalent vaccine introduction in South Africa, which analyzed replacing aP pentavalent vaccine and Hep B by the hexavalent combination. The authors concluded that implementing a hexavalent vaccine in South Africa was highly recommended, because it reduces healthcare provider costs by simplifying logistics and delivery infrastructure: reduced clinic visits, vaccination errors, number of injections and side effects, which can be expected to translate to better acceptability, convenience and increased compliance [41].

The strengths of our analysis are that we utilized nationally available data, or taken from peer-reviewed scientific publications. Our analysis also produced results which are consistent with other previous analyses reported. One of the possible weaknesses of our analysis is that it relies on the assumption that the hexavalent vaccine has similar efficacy to the currently used vaccines. If this assumption were subsequently shown to be inaccurate, then the approach we took here (cost-minimization) would no longer be appropriate.

Table 6 Costs distribution according to scenario 1 to 4 from the societal perspective

| Scenario | Unitary cost (US$) | Amount | Total (US$) |
|----------|-------------------|--------|-------------|
| Scenario 1 |                  |        |             |
| Hexavalent (DTaP-IPV-HepB-Hib) vaccine | 19.80 | 997,877 | 19,757,965 |
| Pentavalent (DTwp-Hib-HepB) vaccine | 2.85  | 966,933 | 2,754,539  |
| Average IPV (1) + bOPV (3) = 3.6 + (0.32*3) = 4.5 | 1.14  | 966,933 | 1,102,304  |
| Difference of schemes | 15.81 | 966,933 | 15,288,431 |
| Additional costs of the simultaneous scheme |        |        | 8,838,805  |
| Cost to society |                  |        | 6,449,627  |
| Scenario 2 |                  |        |             |
| Hexavalent (DTaP-IPV-HepB-Hib) vaccine | 19.80 | 997,877 | 19,757,965 |
| Pentavalent (DTwp-Hib-HepB) vaccine | 2.85  | 966,933 | 2,754,539  |
| IPV four doses- average = 3.60 | 3.6   | 966,933 | 3,480,959  |
| Difference of schemes | 13.35 | 966,933 | 12,909,776 |
| Additional costs of the simultaneous scheme |        |        | 8,838,805  |
| Cost to society |                  |        | 4,070,971  |
| Scenario 3 |                  |        |             |
| Hexavalent (DTaP-IPV-HepB-Hib) vaccine | 19.80 | 997,877 | 19,757,965 |
| Pentavalent (DTwp-Hib-HepB) vaccine | 2.85  | 966,933 | 2,754,539  |
| IPV four-dose bottle plus syringe = 2.10 | 2.10  | 966,933 | 2,030,559  |
| Difference of schemes | 14.85 | 966,933 | 14,360,176 |
| Additional costs of the simultaneous scheme |        |        | 8,838,805  |
| Cost to society |                  |        | 5,521,371  |
| Scenario 4 |                  |        |             |
| Hexavalent (DTaP-IPV-HepB-Hib) vaccine | 19.80 | 997,877 | 19,757,965 |
| Pentavalent (DTwp-Hib-HepB) vaccine | 2.85  | 966,933 | 2,754,539  |
| IPV four doses- pre-filled syringe = 5.10 | 5.10  | 966,933 | 4,931,358  |
| Difference of schemes | 11.85 | 997,877 | 11,459,377 |
| Additional costs of the simultaneous scheme |        |        | 8,838,805  |
| Cost to society |                  |        | 2,620,572  |

bOPV bivalent oral polio vaccine, IPV inactivated polio vaccine
Contrary evidence exists on the aP vs. wP benefits. On one side, concerns about the immunity conferred by aP vaccines not being as complete or as long lasting as that with wP vaccines [42], and it is also possible that the immunity elicited by wP vaccines may better protect against colonization and transmission than that elicited by aP vaccines [43, 44]. On the other side, some studies documented that the switch to aP vaccines reduced all-cause hospitalization in infants [45], and that this would expected to reduce global costs.

Our analysis may have underestimated the benefits of switching to a new hexavalent scheme since the reduction in immunizations required, might well be valued by the parents involved, leading to increased coverage and/or improved timeliness of infants immunization, which isn’t captured in our analysis [19–22].

Conclusions
The introduction of a hexavalent (DTaP-IPV-HepB-Hib) vaccine into the immunization schedule in Chile would lead to additional acquisition costs, which would be partially offset by improved logistics, and a reduction in adverse events associated with the 2016 vaccines. This analysis provides decision makers with additional information on the potential impact of changes to the vaccination schedule caused by technical innovations, whilst reflecting the likely supply of alternative vaccines.

Abbreviations
aP: Acellular pertussis vaccine component; DP: Diphtheria and pertussis; DTP: Diphtheria, tetanus and pertussis; GPEI: Global Polio Endgame Initiative; HepB: Hepatitis B vaccine component; Hib: Haemophilus influenzae type b; IPV: Inactivated polio vaccine; OPV: Oral polio vaccine; PAHO: Pan American Health Organization; wP: Whole-cell pertussis vaccine component; WHO-SAGE: World Health Organization, Strategic Advisory Group of Experts

Acknowledgments
We would like to thank Richard Glover and Keith Evans, of Springer Healthcare Communications for editorial assistance with the preparation of this manuscript. This assistance was funded by Sanofi Pasteur.

Authors’ contributions
IO, HD, FPA and JGLY contributed to the conceptual design of the study and methodology. IO, HD, JGLY, CG, JPT, GM and LL participated in data collection, data analysis and interpretation of data generated. FPA performed a critical review of the overall project. All authors contributed to the critical revision of the article and final approval of the version to be published.

Funding
This research was funded by Sanofi Pasteur.

Availability of data and materials
All data generated or analysed during this study are included in this published article (and its supplementary information files).

Ethics approval and consent to participate
Not applicable; study did not involve human participants.

Consent for publication
All author approved the version to be published.

Competing interests
HD, FPA and JGLY are employees of Sanofi. The authors declare that they have no other competing interests.

Author details
1Centro de Investigaciones Económicas, CINVE, Salud, Montevideo, Uruguay.
2Sanofi Pasteur, Montevideo, Uruguay.
3Chile Departamento de Pediatría y Cirugía Infantil Oriente, Facultad de Medicina, Universidad de Chile, Santiago, Chile.
4Sanofi Pasteur, Lyon, France.
5Sanofi, Avenida Universidad 1738, Coyoacan, 04000 Mexico City, Mexico.

Received: 4 December 2019 Accepted: 17 March 2020
Published online: 09 April 2020

References
1. Bloom DE. The value of vaccination. Adv Exp Med Biol. 2011;697:1–8.
2. Barnighausen T, Berkley S, Bhutta ZA, Bishai DM, Black MM, Bloom DE, Constenla D, Diessen J, Edmunds J, Evans D, et al. Reassessing the value of vaccines. Lancet Glob Health. 2014;2(5):e251–2.
3. Ozawa S, Stack ML, Bishai DM, Mirelman A, Friberg IK, Niessen L, Walker DG, Levine GS. During the ‘decade of vaccines,’ the lives of 6.4 million children valued at $231 billion could be saved. Health Aff (Millwood). 2011;30(6):1010–20.
4. World Health Organization. Poliomyelitis. 2019. http://www.who.int/news-room/factsheets/detail/poliomyelitis. Accessed 23 March 2020.
5. Centers for Disease Control and Prevention. Poliomyelitis and Prevention of Vaccine-Preventable Diseases. 13th ed. The Pink Book; 2015. https://www.cdc.gov/vaccines/pubs/pinkbook/polio.html. Accessed 23 March 2020.
6. Greene SA, Ahmed J, Datta SD, Burns CC, Quddus A, Verteefeuille JF, Wassilak SFG. Progress toward polio eradication - worldwide, January 2017-March 2019. MMWR Morb Mortal Wkly Rep. 2019;68(20):458–62.
7. Nielsen NM, Kay L, Wanscher B, Røsen R, Kjellberg J, Jensnum P. Long-term socio-economic consequences and health care costs of poliomyelitis: a historical cohort study involving 3606 polio patients. J Neurol. 2016;263(6):1120–8.
8. World Health Organization. Polio vaccines and routine polio immunization in the preeradication era. 2010. http://www.who.int/immunization/sage/WHO_position_paper_on_poli_vaccines__Draft_2_March_2010.pdf. Accessed 23 March 2020.
9. World Health Organization. Polio vaccines position paper. 2016. https://www.who.int/immunization/policy/position_papers/polio/en/. Accessed 23 March 2020.
10. Lopalco PL. Wild and vaccine-derived poliovirus circulation, and implications for polio eradication. Epidemiol Infect. 2017;145(3):413–9.
11. Sutter RW, Platt L, Mach O, Jafari H, Aylward RB. The new polio eradication end game: rationale and supporting evidence. J Infect Dis. 2014;210(Suppl 1):S434–8.
12. Pallansch MA. Ending use of Oral poliovirus vaccine - a difficult move in the polio endgame. N Engl J Med. 2018;379(9):801–3.
13. Communicable Disease Center. Poliomyelitis surveillance. 1962. https://stacks.cdc.gov/view/cdc/43716/cdc_43716_DS1.pdf. Accessed 23 March 2020.
14. Ministerio de Salud Chile. Poliomeliticos. 2015. http://www.minsal.cl/poliomeliticos/. Accessed 23 March 2020.
15. Global Polio Eradication Initiative. Introduction of inactivated polio vaccine (IPV) in routine immunizations. 2014. http://www.who.int/immunization/diseases/poliomyelitis/Inactivated_polio_vaccine/IPV_operational_manual.pdf. Accessed 23 March 2020.
16. World Health Organization. The Polio Endgame Strategy 2019-2023: Eradication, Integration, Containment and Certification. 2019. http://polioeradication.org/who-we-are/polio-endgame-strategy-2019-2023/. Accessed 23 March 2020.
17. Nunes MC, Madhi SA. Review of a new fully liquid, hexavalent vaccine: Hexaxim. Expert Opin Biol Ther. 2013;13(4):575–93.
18. Maman K, Zoller Y, Greco D, Duur G, Sendyona S, Remy V. The value of childhood combination vaccines: from beliefs to evidence. Hum Vaccin Immunother. 2015;11(9):2132–41.
19. Marshall GS, Happe LE, Lunacek OE, Szynski MD, Woods CR, Zahn M, Russell A. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J. 2007;26(6):496–500.
20. Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt HJ, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J. 2006;25(6):507–12.
21. Dodd D. Benefits of combination vaccines: effective vaccination on a simplified schedule. Am J Manag Care. 2005;9(1 Suppl):S6–12.
22. Koslap-Petraco MB, Judelsohn RG. Societal impact of combination vaccines: experiences of physicians, nurses, and parents. J Pediatr Health Care. 2008;22(5):300–9.
23. Ministerio de Salud deChile. Calendario de vacunación. 2018. https://vacunas.minsal.cl/calendario-de-vacunacion-2018/. Accessed 7 January 2019.
24. Ministerio de Salud deChile. Calendario de Vacunacion 2019. 2019. https://vacunas.minsal.cl/calendario-de-vacunacion-2019/. Accessed 7 January 2019.
25. Glassman A, Canon Q, Silverman R. How to get cost-effectiveness analysis right? The case of vaccine economics in Latin America. Value Health. 2016;19(8):913–20.
26. Pan American Health Organization. Promotion of evidence-based decision making for the introduction of new vaccines. 2018. https://www.paho.org/hq/index.php?option=com_content&view=article&id=13239&Itemid=841. Accessed 23 March 2020.
27. Instituto Nacional de Estadísticas Chile. Proyecciones de población. Proyección de población 2002-2020. 2017. https://www.ine.cl/estadisticas sociales/demografia-y-vitales/proyecciones-de-poblacion. Accessed 12 May 2017.
28. Ministerio de Salud de Chile. Programa Nacional de Inmunizaciones. 2017. http://www.minsal.cl/programa-nacional-de-inmunizaciones/. Accessed 22 May 2017.
29. World Health Organization, WHO/UNICEF coverage estimates for 1980–2015. As of 15 July 2016. 2016. http://www.who.int/immunization/monitoring_surveillance/routine/coverage/en/index4.html. Accessed 23 March 2020.
30. Decker MD, Edwards KM, Steinhoff MC, Rennels MB, Pichichero ME, Englund JA, Anderson EL, Deloria MA, Reed GF. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics. 1995;96(3 Pt 2):S57–66.
31. Centres for Disease Control and Prevention. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(RR-7):1–25.
32. Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics. 1981;68(5):650–60.
33. De Coster I, Fournie X, Faure C, Ziani E, Nicolas L, Soubeyrand B, Van Damme P. Assessment of preparation time with fully-liquid versus non-fully liquid paediatric hexavalent vaccines. A time and motion study. Vaccine. 2015;33(32):3976–82.
34. Arancel MAI. MINSAL Chile. In: Comprehensive medical consultation, Medium Complexity Hospital, Equivalent Emergency Service; 2018.
35. Arancel MAI. MINSAL Chile. In: Comprehensive medical consultation, Medium Complexity Hospital, Equivalent Emergency Service; 2018.
36. CENABAST. Central supply of the National System of health services (CENABAST). Chile: Ministry of Health; 2018.
37. Pan American Health Organization. WHO/UNICEF coverage estimates for 1980-2016. Vaccine. 2018;36(49):7568–73.
38. Ministry of Health of Chile. Calendario de vacunación. 2019. https://vacunas.minsal.cl/calendario-de-vacunacion-2019/. Accessed 7 January 2019.
39. Fagnani F, Le Fur C, Durand I, Gibergy M. Economic evaluation of a combined DTPa, hepatitis B, polo, Hib vaccine. Potential impact of the introduction of Hexaxim® vaccine in the French childhood immunisation schedule. Eur J Health Econ. 2004;5(2):143–9.
40. Masescarenas A, Salinas J, Tasset-Tisseau A, Masescarenas C, Khan MM. Polo immunization policy in Mexico: economic assessment of current practice and future alternatives. Public Health. 2005;119(6):542–9.
41. Mogale K, Burnett RJ, Olivier D, Mphalele J. Economic assessment of implementing Hexaxim® vaccine within the south African expanded Programme on immunisation (EPI-SA). Int J Infect Dis. 2014;21S:430.
42. Jackson DW, Rohani P. Perplexities of pertussis: recent global epidemiological trends and their potential causes. Epidemic Infect. 2014;142(4):672–84.
43. Smallridge WE, Rolin OY, Jacobs NT, Harvill ET. Different effects of whole-cell and acellular vaccines on Bordetella. J Infect Dis. 2014;209(12):1981–8.
44. Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci U S A. 2014;111(2):787–92.
45. Desai S, Scharzer DL, Silva A, Rotondo J, Squires SG. Trends in Canadian infant pertussis hospitalizations in the pre- and post-acellular vaccine era, 1981-2016. Vaccine. 2018;36(49):7568–73.